Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.

Clinical lung cancer - 1 Sept 2018

Oh In-Jae, Hur Jae Young, Park Cheol-Kyu, Kim Young-Chul, Kim Seung Joon, Lee Min Ki, Kim Hee Joung, Lee Kye Young, Lee Jae Cheol, Choi Chang-Min

Abstract excerpt

INTRODUCTION: HER2 mutations are found in 2% to 4% of non-small-cell lung cancer cases and are usually mutually exclusive with other genetic alterations. We screened a large cohort of patients from multiple institutions in Korea, described the characteristics of HER2-mutant cases, and reported on several patients who were treated with pan-HER inhibitors. PATIENTS AND METHODS: The study population consisted of 360...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Quinazolines

Share to Receptor, ErbB-2

Share to Survival Rate

Source

Identifiers

PMID: 30149884
DOI: 10.1016/j.cllc.2018.05.018

Genes

ALK
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.PMID 30149884Read ↗

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.Semantic proximity Read ↗

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.Semantic proximity Read ↗

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesSemantic proximity Read ↗

Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.Semantic proximity Read ↗

[Current management and future prospect of HER-2 mutant non-small cell lung cancer].Semantic proximity Read ↗

Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.Semantic proximity Read ↗

HER2 mutations in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power.Semantic proximity Read ↗

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.Semantic proximity Read ↗

[Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Role of HER2 in NSCLC].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.